Can an on­colyt­ic virus ther­a­py chal­lenge the stan­dard of care in blad­der can­cer? CG On­col­o­gy has $120M to find out

CG On­col­o­gy is cash­ing in on its in­ter­im da­ta up­date.

Tues­day morn­ing, the Irvine, CA-based biotech an­nounced that it raised $120 mil­lion — eclips­ing the com­bined $87 mil­lion it’s brought in since its in­cep­tion 12 years ago. The raise comes af­ter CG post­ed up­dat­ed da­ta at SITC for its on­colyt­ic virus can­di­date in com­bi­na­tion with Keytru­da for non-mus­cle in­va­sive blad­der can­cer, or NMIBC, in pa­tients who did not re­spond to stan­dard Bacil­lus Cal­mette-Guérin (BCG) ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER